JOHN ADENIJI: Open Payments
NPI 1003280892 · REDLANDS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$12,254 in 279 payments from 17 companies in 2025. Trend: 2023 $4,433 · 2024 $8,275 · 2025 $12,254
Food & beverage: $5,560Speaker / faculty: $4,939Consulting: $1,120Travel & lodging: $407Education: $228
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 42 | $5,511 |
| Biogen, Inc. | 2 | $1,792 |
| ABBVIE INC. | 56 | $1,198 |
| Teva Pharmaceuticals USA, Inc. | 35 | $863 |
| Neurocrine BioSciences, Inc. | 27 | $568 |
| Alkermes, Inc. | 25 | $528 |
| E.R. Squibb & Sons, L.L.C. | 25 | $497 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 18 | $469 |
| Janssen Pharmaceuticals, Inc | 21 | $371 |
| Lundbeck LLC | 12 | $162 |
Products named: REXULTI, VRAYLAR, ZURZUVAE, INGREZZA, COBENFY, CAPLYTA, UZEDY, INVEGA SUSTENNA.
Industry payments across CA — which companies pay providers there.
